Literature DB >> 9114908

Bioavailability and absorption kinetics of nicotine following application of a transdermal system.

S K Gupta1, N L Benowitz, P Jacob, C N Rolf, J Gorsline.   

Abstract

1. The absolute bioavailability and absorption kinetics of nicotine were investigated in 13 healthy adult male smokers following single and multiple applications of a nicotine transdermal system (NTS), designed to release nicotine at an approximate rate of 1.5 mg h-1 over 24 h. The absorption of nicotine from the single NTS application was calculated with reference to a simultaneous intravenous infusion (i.v.) of deuterium-labelled nicotine. 2. The mean input time (MIT) and mean absorption time (MAT) for nicotine following application of NTS for 24 h were 7.7 and 4.2 h, respectively. 3. Following NTS removal, the mean apparent nicotine elimination half-life was 2.8 h, compared with 2.0 h following i.v. nicotine, reflecting continued absorption of nicotine following NTS removal. 4. The mean amount of nicotine absorbed from the NTS after the 24 h application was 20.9 mg, which represents about 68% of the amount released from the system; the remaining 32% was lost from the system during daily activities. 5. The ratio of AUC values for the metabolite cotinine relative to nicotine was similar whether nicotine was administered transdermally or intravenously. 6. Following i.v. administration, the mean nicotine clearance was 72 l h-1 (coefficient of variation 29%). Since coefficients of variation in AUC values following NTS and i.v. treatments were similar, transdermal administration of nicotine was not associated with increased interindividual variability in plasma nicotine concentrations. 7. No significant changes were seen in the pharmacokinetics of nicotine between single and multiple applications of NTS. 8. As expected from the higher total plasma nicotine concentrations, the incidence of adverse effects was higher following simultaneous intravenous and transdermal administration of nicotine. The most frequently reported systemic side effects were nervousness and headache: mild itching was the most frequent topical effect.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 9114908      PMCID: PMC1364642          DOI: 10.1111/j.1365-2125.1993.tb04221.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Pharmacokinetics of multiple daily transdermal doses of nicotine in healthy smokers.

Authors:  H D Ross; K K Chan; A J Piraino; V A John
Journal:  Pharm Res       Date:  1991-03       Impact factor: 4.200

2.  Determination of mean input time, mean residence time, and steady-state volume of distribution with multiple drug inputs.

Authors:  N Watari; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1989-10

3.  Drug accumulation.

Authors:  J G Wagner
Journal:  J Clin Pharmacol J New Drugs       Date:  1967 Mar-Apr

4.  Influence of tobacco abstinence on the disposition kinetics and effects of nicotine.

Authors:  B L Lee; N L Benowitz; P Jacob
Journal:  Clin Pharmacol Ther       Date:  1987-04       Impact factor: 6.875

5.  Interindividual variability in the metabolism and cardiovascular effects of nicotine in man.

Authors:  N L Benowitz; P Jacob; R T Jones; J Rosenberg
Journal:  J Pharmacol Exp Ther       Date:  1982-05       Impact factor: 4.030

6.  Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: absence of an isotope effect in the clearance of (S)-nicotine-3',3'-d2 in humans.

Authors:  P Jacob; L Yu; M Wilson; N L Benowitz
Journal:  Biol Mass Spectrom       Date:  1991-05

7.  Single- and multiple-dose pharmacokinetics of Nicoderm (Nicotine Transdermal System).

Authors:  S K Gupta; R A Okerholm; P Coen; R D Prather; J Gorsline
Journal:  J Clin Pharmacol       Date:  1993-02       Impact factor: 3.126

8.  Cyclosporin-phenytoin interaction: re-evaluation using metabolite data.

Authors:  M Rowland; S K Gupta
Journal:  Br J Clin Pharmacol       Date:  1987-09       Impact factor: 4.335

9.  Stable isotope method for studying transdermal drug absorption: the nicotine patch.

Authors:  N L Benowitz; K Chan; C P Denaro; P Jacob
Journal:  Clin Pharmacol Ther       Date:  1991-09       Impact factor: 6.875

10.  Steady-state pharmacokinetics and dose relationship of nicotine delivered from Nicoderm (Nicotine Transdermal System).

Authors:  J Gorsline; S K Gupta; D Dye; C N Rolf
Journal:  J Clin Pharmacol       Date:  1993-02       Impact factor: 3.126

View more
  13 in total

1.  Population pharmacokinetic model of transdermal nicotine delivered from a matrix-type patch.

Authors:  Matthew W Linakis; Joseph E Rower; Jessica K Roberts; Eleanor I Miller; Diana G Wilkins; Catherine M T Sherwin
Journal:  Br J Clin Pharmacol       Date:  2017-09-06       Impact factor: 4.335

2.  Transcutaneous nicotine does not prevent postoperative nausea and vomiting: a randomized controlled trial.

Authors:  Christoph Czarnetzki; Eduardo Schiffer; Christopher Lysakowski; Guy Haller; Daniel Bertrand; Martin R Tramèr
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

3.  Concentration dependency in nicotine skin penetration flux from aqueous solutions reflects vehicle induced changes in nicotine stratum corneum retention.

Authors:  Rina Kuswahyuning; Michael S Roberts
Journal:  Pharm Res       Date:  2014-01-23       Impact factor: 4.200

4.  Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis.

Authors:  Mathilde Marchand; Patrick Brossard; Henri Merdjan; Nicola Lama; Rolf Weitkunat; Frank Lüdicke
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-12       Impact factor: 2.441

5.  Attention-enhancing effects of propranolol and synergistic effects with nicotine.

Authors:  Britta Hahn; Cory K Olmstead; Marie B Yuille; Joshua J Chiappelli; Ashleigh K Wells
Journal:  Cogn Affect Behav Neurosci       Date:  2020-06       Impact factor: 3.282

6.  Effect of transdermal nicotine replacement on alcohol responses and alcohol self-administration.

Authors:  Sherry A McKee; Stephanie S O'Malley; Julia Shi; Tricia Mase; Suchitra Krishnan-Sarin
Journal:  Psychopharmacology (Berl)       Date:  2007-10-03       Impact factor: 4.530

7.  Effects of nicotine on novelty detection and memory recognition performance: double-blind, placebo-controlled studies of smokers and nonsmokers.

Authors:  Brett Froeliger; David G Gilbert; F Joseph McClernon
Journal:  Psychopharmacology (Berl)       Date:  2009-06-02       Impact factor: 4.530

8.  A test of the cognitive self-medication hypothesis of tobacco smoking in schizophrenia.

Authors:  Britta Hahn; Alexander N Harvey; Marta Concheiro-Guisan; Marilyn A Huestis; Henry H Holcomb; James M Gold
Journal:  Biol Psychiatry       Date:  2013-05-06       Impact factor: 13.382

9.  A preliminary study on the effect of combined nicotine replacement therapy on alcohol responses and alcohol self-administration.

Authors:  Tomoko Udo; Emily L R Harrison; Julia Shi; Jeanette Tetrault; Sherry A McKee
Journal:  Am J Addict       Date:  2013-04-11

10.  Evidence for positive allosteric modulation of cognitive-enhancing effects of nicotine in healthy human subjects.

Authors:  Britta Hahn; Megan E Shrieves; Cory K Olmstead; Marie B Yuille; Joshua J Chiappelli; Edna F R Pereira; Edson X Albuquerque; William P Fawcett
Journal:  Psychopharmacology (Berl)       Date:  2019-11-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.